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ABSTRACT

Article Type:

Although there is no definitive evidence that coronavirus disease 2019 (COVID-19) affects
the kidneys adversely, amongst those who develop severe COVID-19 infection and require
hospitalization, acute kidney injury (AKI) was reported. Here, we report the clinical outcome
associated with AKI in a 32-year-old man with confirmed COVID-19 infection with no prior
history of renal malfunction. The AKI was identified during intensive care unit (ICU) course
with the median creatinine and blood urea nitrogen values of 3.1 mg/dL (normal value: 0.6-1.2
mg/dL) and 145 mg/dL (normal value:15-45 mg/dL), respectively. Renal function of patients
hospitalized with COVID-19 infection needs to be monitored regularly to intervene as early
as possible and to prevent the development of AKI and further kidney complications.
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Implication for health policy/practice/research/medical education:

In the era of COVID-19 pandemic, renal function of the patients–with confirmed COVID-19 infection–needs to be regularly
monitored during the hospitalization time to intervene as early as possible in order to curb the development of acute renal injuries
(AKIs). Future epidemiological studies are warranted to determine the cause-effect relationship between COVID-19 and AKI.
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M, et al. COVID-19 and acute kidney injury; a case report. J Renal Inj Prev. 2020; 9(3): e26. doi: 10.34172/jrip.2020.26.

Introduction
Acute respiratory failure and diffuse alveolar damage are
common clinical features of coronavirus disease 2019
(COVID-19) infection in hospitalized patients and can
lead to multiple organ injuries. So far, there is no definitive
evidence that COVID-19 infection affects the kidneys
adversely. However, amongst those who develop severe
infection and require hospitalization, acute kidney injury
(AKI) was reported (1). We aim to present the clinical
outcome associated with AKI in a case with confirmed
COVID-19 infection.
Case Presentation
A 32-year-old man was admitted to Ardabil medical
educational hospital in northwestern Iran on March 14th,
2020 with a 4-day headache, myalgia, dry cough, shortness

of breath, and fever ~38°C. He worked in a restaurant as
a chef and reported that he had not traveled to a foreign
country in the past 6-month but had contact with his
co-worker who was coughing few days before the onset
of his symptoms. The patient was admitted for suspected
viral pneumonia in the emergency department. On
admission day, transverse thoracic computed tomography
(CT) scan showed patchy areas of ground-glass opacities
with consolidation indicating the possibility of viral
pneumonia (Figure 1). Appropriate antibiotics and
hydroxychloroquine started on the admission day.
Nasopharyngeal and oropharyngeal swabs were taken
and tested positive for SARS–CoV-2 by real-time reversetranscription polymerase chain reaction (rRT-PCR) assay.
None of the patient’s family members developed COVID19-related symptoms, at the time of writing this report.
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urea, troponin, potassium and neutrophil/lymphocyte
ratio. According to the kidney disease improving global
outcomes classification (2), AKI is defined by an increase
in serum creatinine over baseline (2,3). For this patient,
AKI was identified during ICU course with the median
creatinine and blood urea nitrogen values as 3.1 mg/dL
(normal value:0.6-1.2 mg/dL) and 145 mg/dL (normal
value:15-45 mg/dL), respectively.
Once the patient transferred to the ICU,
hydroxychloroquine was discontinued, and the patient
was treated with the antiviral agent (i.e., Kaletra),
meropenem, Targosid, and azithromycin for probable
secondary bacterial lung infections. All the medications
were adjusted with glomerular filtration rate during the
ICU stay and the patient received appropriate intravenous
fluid management. To manage respiratory failure, the
patient was supported by mechanical ventilation using
volume-controlled mode with low tidal volume strategy
(6 cc/kg), high positive end-expiratory pressure level
and maintain of plateau pressure below 30 cm H2O.
Thrombosis prophylaxis with heparin and stress ulcer
prophylaxis with pantoprazole was administered during
the hospitalization. At the time of writing this report, the
patient was transferred from ICU to the hospital ward.

Figure 1. CT images of a 32-year-old patient with SARS-CoV-2. Note:
Upper panel CT images were taken on day 1 (admission day) and bottom
panels CT image were taken on day 7 of hospitalization. Left bottom
panel show extensive ground glass opacities and occasional foci of
consolidation.

On day 3, the patient was transferred to the intensive care
unit (ICU) to receive ventilatory support. On day 7, the
CT scan was repeated and showed multilobar bilateral
lung consolidation with ground-glass opacities (Figure 1).
Table 1 shows the laboratory findings on admission day
and during the ICU course. During the first three days of
hospitalization, the patient reported no prior history of
renal malfunction and his routine laboratory test results
were within normal ranges. However, starting from day
4, the values of some blood indicators were above the
normal range including white blood cells, creatinine,

Discussion
This report describes a critically ill patient who presented
with laboratory-confirmed COVID-19 associated
symptoms. The AKI for this patient was identified during
the ICU course, which was consistent with previous studies
showing AKI in hospitalized patients with confirmed
COVID-19 (1) and contradicted another study that
indicated COVID-19 infection does not result in AKI (4).
Nevertheless, AKI was recognized as an independent risk
factor for patients’ in-hospital mortality due to COVID-19

Table 1. Laboratory Data at Hospital Admission and ICU course from day 1 to 16

Day 8

Day 9

Day
10

Day 11

Day
12

Day 13

Day
14

Normal range

Day 1

Day 4

Day 6

Day 7

Day 15

Day 16

Creatinine

0.6-1.2 mg/dL

1.1

2.0

4.0

––

4.0

––

3.4

––

3.1

––

2.7

––

2.8

Urea

15-45 mg/dL

35

63

61

––

169

––

148

––

145

––

161

––

129

Na

132-145 mEq/L

134

136

134

––

143

––

138

––

135

––

139

––

141

K

3.5-5.0 mEq/L

4.6

6

4.9

––

4.3

––

4.3

––

4.5

––

4.7

––

6.5

WBCs

4000-10000/
mcL

23200

31800

––

12800

––

15800

––

18400

––

16400

––

18700

13900

Hb

13.5-17.5 g/dL

15.6

14.2

––

10.7

––

12.2

––

12.1

––

11.0

––

10.9

8.4

Platelet
count

150000450000/mcL

301000

399000

––

287000

––

385000

––

462000

––

393000

––

7%

6%

––

5%

––

4%

––

7%

––

10%

––

12%

11%

1624

1908

––

640

––

632

––

1288

––

1640

––

2244

1529

2.2

0.18

––

––

––

––

––

––

––

––

––

––

––

Lymphocyte
20-40 percent
percent
Lymphocyte 1000-4800/
count
mc/L
Troponin

<0.03

380000 234000

Abbreviations: Na, sodium; K, potassium; WBCs, white blood cells; Hb, hemoglobin.
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(5). Even minor acute variations in kidney function
can result in short- and long-term dire consequences,
including chronic kidney disease, end-stage renal disease,
and decease (3,6). Evidence shows that microvascular
dysfunction, inflammation, and metabolic disorders are
the main mechanisms of AKI (2,7). Therefore, amidst
the COVID-19 pandemic, which is already taking a toll
on global health, early diagnosis and identification of
the underlying etiology are essential to guide proper
management. Appropriate infectious control, intravenous
fluid management, and respiratory failure management
can contribute to preventing further AKIs (2,7-9).
Conclusion
In sum, renal function of patients hospitalized with
COVID-19 infection needs to be monitored regularly

to intervene as early as possible and to prevent the
development of AKI. Additional studies are warranted
to determine the cause-effect relationship between
COVID-19 and AKI.
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